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In the present report, a 73 years-old male patient who developed clear cell type renal cell carcinoma
(RCC) 5 years after the diagnosis of chronic lymphocytic lymphoma (CLL) and plausible explanations for
this association were discussed by the authors. The incidence of CLL and RCC occurring in the same
patient is higher than that expected in the general population. Various explicative hypotheses of this
concurrence include treatment-related development of a second malignancy, immunomodulatory me-
chanisms, viral aetiology, cytokine (interleukin 6) release from a tumor, and common genetic mutations.
Further investigations are warranted.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The increased incidence of second primary solid tumors and
hematological malignancies have been reported in the setting of
Non-Hodgkin lymphoma (NHL) [1,2]. The observed rates of renal
cell carcinoma (RCC) developing in the NHL patients was 1.86-fold
greater, and conversely, NHL developing in RCC patients was 2.67-
times higher than that the expected rates in the general popula-
tion [3]. There appears to be an association between lymphoid
malignancies and RCC that cannot be explained by chance alone.
This co-existence should be attributed to prior treatment mod-
alities such as alkylating agents, long-term survival of elderly pa-
tients, close monitorization of NHL with imaging studies, im-
munosuppression due to underlying lymphoproliferative disorder,
genetic alterations predisposing to both malignancies, environ-
mental factors, and viral aetiology [1,2,4]. However, the exact
mechanism has not been clariﬁed yet.2. Case report
A 73 year-old man was diagnosed with chronic lymphocytic
lymphoma (CLL) in December 2009, where he presented with a
servical mass at another state hospital. He was treated with 6 cy-
cles of cyclophosphamide, vincristine and prednisone (CVP). On
follow-up he received 6 cycles of ﬂudarabine because of relapsed
disease. His past history showed a 60 year/pack cigarette usage.Ltd. This is an open access article u
).His family and social histories were unremarkable. He was referred
to our center with B symptoms, and axillary lymphadenopathies in
December 2012. His physical examination was unremarkable ex-
cept bilateral axillary and left posterior servical lymphadeno-
pathies. His blood count parameters were as follows: hemoglobin
(Hb): 14.5 g/dL, MCV: 90.3 fL, leukocyte: 20.08103/mm3, lym-
phocyte: 14.19103/mm3, platelet count (Plt): 168103/mm3.
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
values were 71 mm/h and 6 mg/L (normal range: 0–5), respec-
tively. All other laboratory tests including serum electrolytes, liver
and renal function tests, and coagulation proﬁle were normal. Bi-
lateral multiple axillary lymphadenopathies (73.5 cm2 in the
right, 63.5 cm2 in the left) were noted in the superﬁcial ultra-
sonography. Six cycles of ﬂudarabine and cyclophosphamide (FC)
combination were applied from December 11, 2012 to April 30,
2013, resulting in relief from symptoms and achieving a partial
remission in lymphadenopathies. The patient applied with deep
anemia (Hb: 3.6 g/dL) and thrombocytopenia (Plt: 35103/mm3)
in April 2014, one year from the last chemotherapy. However, er-
ythropoietin (EPO) level was 2030 mIU/mL (normal range: 4.3–20).
ESR and CRP values were 136 mm/h and 221 mg/L, respectively.
Bone marrow biopsy revealed hypercellularity (%60), and grade III
increment for iron and reticular ﬁbers. There were no abnormality
in erythrocytic and granulocytic series in terms of differentiation
and maturation. No inﬁltration or granuloma was noted. In addi-
tion, dismegacaryopoiesis and an increase in the number of the
megacaryocytes were also reported (Fig. 1). Direct and indirect
antiglobulins tests (initial and repeated) were negative, and re-
ticulocyte correction index was 0.04. Detailed laboratory in-
vestigations including viral aetiology, rheumatological parameters,
and tumor markers were unremarkable. JAK2 (V617F) mutationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The bone marrow histopathology shows hypercellularity, sparse clustering
and increase in megacaryocytes, and dismegacaryopoiesis (Hematoxylin-eosin,
200 ).
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September 2014, revealed a mild splenomegaly (13.3 cm) without
hepatomegaly, and a heterogen solid mass in 778 cm dia-
meter bearing cystic areas in the medial lower pole of the left
kidney. Tru-cut biopsy of the renal mass showed vimentin (þ),
CD10 (þ), Ki-67: 10–20%, EMA (þ), LMWK (þ) cells which were
consistent with clear cell type RCC (Fig. 2a–d). Torax CT to rule out
a probable metastasis of RCC was found to be negative. Surgical
removal of the aforementioned lesion was planned. Unfortunately,
on-follow up, he developed tonic-clonic seizures for two times
every other day. Electroencephalography recorded normal brain
activities. Brain magnetic resonance imaging did not detect any
bleeding or mass lesion. Intravenous administration of sodium
valproate was initiated following improvement in seizures. How-
ever, the general condition of the patient worsened and he expired
on December 2014 with active RCC.Fig. 2. (a) The tumor is characterized by malignant cells with clear cytoplasm in high
(immunoperoxidase, 200 ), (c) CD10 positivity in tumoral cells (immunoperoxidase, 2
keratin (LMWK) (immunoperoxidase, 200 ).3. Discussion
Although second malignancies are increasingly observed after
NHL, the incidence of CLL and RCC in the same patient is excep-
tional [4,5]. Nishikubo et al. [4] reported a case series of 8 patients
with lymphoid malignancies and RCC. In 2 of 8 patients, CLL and
T-cell CLL were diagnosed 1 year and 8 months prior to RCC, re-
spectively. More recently, in a series of 9 patients with lymphoma
and RCC, only 1 patient had CLL [5]. This patient had carried a
diagnosis of CLL for 15 years without any treatment. Finally, a case
series of 5 patients with concomitant lymphoid malignancies and
RCC were reported by Serefhanoglu et al. [6] Three of 5 patients
had CLL. In 2 of 3 patients, the CLL was diagnosed prior (13 months
and 5 years, respectively) to their RCC; while in 1 patient coin-
cidence of CLL and RCC was reported. Our patient developed RCC
after 5 years in the setting of NHL, and he had been treated with
multiple courses of chemotherapy including both alkylating agents
(12 cycles of cyclophosphamide) and purine analogues (12 cycles
of ﬂudarabine). Although he did not receive radiotherapy, he had
multiple CT scans during his follow-up. Certain chemotherapeutic
regimens have been shown to increase both the risk of NHL and
RCC. Additionally, this increased risk was also attributed to
radiotherapy that the patients received for NHL [2]. The actuarial
risk of developing a second cancer 3–20 years after diagnosis of
NHL was 21%, compared with a population expected cumulative
risk of 15%. NHL patients whom underwent treatment for lym-
phoma are at increased risk for developing RCC, especially o1
year and 410 years after treatment [2]. In contrast, some authors
[3,4,7] identiﬁed patients with simultaneous NHL and RCC whom
did not receive any treatment at the time of presentation, and they
have suggested that this association could not be attributed to
treatment modalities alone. Recently, Dutcher et al. [8] have re-
viewed the current data about the existence of RCC and hemato-
logic malignancies in the same patient. Among these 186 patients,
the most common sequence of diagnosis was a hematologic ma-
lignancy (twelve with CLL) followed by RCC (43%), secondly,magniﬁcence (Hematoxylin-eosin, 400 ), (b) Vimentin positivity in tumoral cells
00 ), and (d) Tumoral cells displaying positivity for low-molecular weight cyto-
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and hematologic malignancy developed later (22%). The authors
have also reported that these patients have common clinical
characteristics, including a male predominance (2.25:1), having a
hematological malignancy of B-cell origin (94%), and showing an
evident risk of extranodal lymphoma (32%). The immune dysre-
gulation via a breakdown in tumor surveillance as a result of
lymphoma predisposes the patient to the development of RCC [3].
Proliferating cell nuclear antigen positivity (Z10%) but not p53 or
human papillomavirus (HPV) DNA correlated with worse clinical
prognosis such as invasion or metastasis of RCC [9]. However, the
role of HPV in RCC is controversial [10]. Sakai et al. [11] suggested
that RCC related interleukin 6 synthesis might stimulate the pro-
liferation of the myeloma cells. Growing evidence supports the
idea that a common genetic mutation can explain the elevated
incidence of second malignancies in patients with NHL. Deletions
of 3p have been described in 95–98% of sporadic clear cell type
RCC [12,13]. In addition, abnormalities in 11p, chromosome 13, and
deletions in 17p in 11–33% of patients with advanced stage RCC
have been reported [12]. Cytogenetic analysis of NHL cells by more
accurate ﬂuorescence in-situ hybridization methods such as ratio-
painting and comparative genomic hybridization have enabled to
identify further unsuspected chromosomal abnormalities includ-
ing 17p deletions, trisomy of chromosome 7, ampliﬁcation of 3
(p12) and mutations in p53 [14]. The persistently increased risk of
second malignancies in the clinical setting of CLL, particularly
those treated with intense courses of chemotherapy, should alert
clinicians to the importance of continued medical surveillance.
Future studies are needed to better clarify if this association is a
causal relationship or coincidental occurrence.Conﬂict of interests
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